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Background: We investigated the effectiveness of a text-message reminder to improve uptake of the English Bowel Cancer
Screening programme in London.
Methods:We performed a randomised controlled trial across 141 general practices in London. Eight thousand two hundred sixty-
nine screening-eligible adults (aged 60–74 years) were randomised in a 1 : 1 ratio to receive either a text-message reminder
(n¼ 4134) or no text-message reminder (n¼ 4135) if they had not returned their faecal occult blood test kit within 8 weeks of initial
invitation. The primary outcome was the proportion of adults returning a test kit at the end of an 18-week screening episode
(intention-to-treat analysis). A subgroup analysis was conducted for individuals receiving an invitation for the first time.
Results: Uptake was 39.9% in the control group and 40.5% in the intervention group. Uptake did not differ significantly between
groups for the whole study population of older adults (adjusted odds ratio (OR) 1.03, 95% confidence interval (CI) 0.94–1.12;
P¼ 0.56) but did vary between the groups for first-time invitees (uptake was 34.9% in the control and 40.5% in the intervention;
adjusted OR 1.29, 95% CI 1.04–1.58; P¼ 0.02).
Conclusions: Although text-message reminders did not significantly increase uptake of the overall population, the improvement
among first-time invitees is encouraging.
Colorectal cancer (CRC) is the fourth most common cancer and
the second leading cause of cancer death in the United Kingdom
(Cancer Research UK, 2016 a, b). In England, the National Health
Service (NHS) runs the Bowel Cancer Screening Programme
(BCSP), an organised CRC screening programme that offers
biennial guaiac faecal occult blood testing (gFOBt) to men and
women aged 60–74 years. Screening is widely recommended for
the early detection of CRC and repeated participation in CRC
screening has been shown to reduce CRC mortality by up to 25%
(Scholefield et al, 2002; Hewitson et al, 2008; Levin et al, 2008;
Sung et al, 2015). However, overall uptake of CRC screening in
England is low at approximately 56% (House of Commons, 2014).
Commonly reported reasons for non-participation in CRC
screening include forgetting or not getting around to completing
the test kit and being too busy (Janz et al, 2007; van Rijn et al, 2008;
van Dam et al, 2013; Lo et al, 2015b). Previous studies have shown
that various modalities of reminders are effective at improving
CRC screening uptake, including telephone and postal reminders
(Baron et al, 2008; Power et al, 2009; Camilloni et al, 2013).
Telephone reminders have been found to be the most effective
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reminder modality, improving CRC screening uptake by up to 21%
(Myers et al, 2007; Segnan et al, 2010; Camilloni et al, 2013;
Davis et al, 2014). However, the cost of telephone reminders is
often prohibitive in the context of publicly funded screening
programmes due to the additional labour they require (Segnan
et al, 2010).
In the United States, a randomised controlled trial (RCT)
examining the effectiveness of a multicomponent strategy to
increase uptake of gFOBt through community health centres found
that text-messages (also referred to as Short Messaging Service),
when used in conjunction with postal and automated telephone
reminders, achieved uptake of 82%, compared with 37% in the
usual care group (Baker et al, 2014). In the context of organised
screening in the United Kingdom, two recent studies found that
preappointment text-message reminders were effective at increas-
ing attendance at routine breast screening appointments (Icheku
and Arowobusoye, 2015; Kerrison et al, 2015). The effectiveness of
text-message reminders to promote uptake of gFOBt in the NHS
BCSP, however, has not been examined (Senore et al, 2015). Unlike
preappointment reminders for the NHS Breast Screening Pro-
gramme, a reminder for CRC screening in the BCSP would act as
an additional prompt to complete and return a gFOBt kit beyond
the standard 4-week postal reminder (Halloran, 2009).
Text-messages are often considered to be the next best
alternative to telephone reminders, as they have the advantage of
providing instant and direct transmission at a low cost (Gurol–
Urganci et al, 2013). They also have an advantage over postal
reminders, as the direct transmission of text-messages to a person’s
mobile phone means they are unlikely to be misplaced as items
sent through the post (Kaplan, 2006). The effectiveness of
delivering text-messages is likely to be influenced by mobile phone
coverage and the accuracy of mobile phone records in the clinical
systems. Mobile technology has the potential to provide outreach
and access to people regardless of socioeconomic status, race,
ethnicity, or location, with 93% of the UK population personally
owning or using a mobile phone (Ofcom, 2016). However,
challenges with integrating mobile technology with primary care
remain, as a recent study reported that only 39.8% of the eligible
population had a registered mobile on their GP’s clinical system
(Kerrison et al, 2015).
The effect of a text-message reminder for CRC screening is
likely to be different based on an individual’s history with the
screening programme, specifically whether they are first-time or
repeat invitees in a given screening round. Uptake at first-time
invitation is the strongest predictor of repeat uptake in the second
round of invitations. A recent population-based study showed that
uptake of the second round of invitations was 87% among people
who previously participated in the first round (Lo et al, 2015a).
In comparison, uptake among people invited for CRC screening
for the first time is only around 54% (von Wagner et al, 2011).
Furthermore, a recent series of trials piloting interventions to
improve uptake of the BCSP in England found that interventions
had a significantly stronger impact among first-time invitees
compared with those who had previously been invited (White et al,
2015). Thus there is greater opportunity to promote uptake among
first-time invitees, which would lead to greater future adherence
among screening-eligible adults.
The primary aim of this RCT was to test the effectiveness of a
text-message reminder to increase gFOBt uptake. The outcome
measure was the total proportion of invitees adequately screened
18 weeks after the initial invitation was sent. Our secondary aims
were to examine whether or not a text-message reminder is more
effective in improving uptake among first-time invitees than repeat
invitees and to establish the efficacy of the text-messages by testing
the effectiveness among the non-responders who also had a
registered mobile number. The findings will be important to show
the impact of the intervention on the overall population and also
the subgroups who are of interest of the text-message reminder
intervention.
METHODS AND MATERIALS
Study design and setting. We performed a two-arm RCT in
London across six Clinical Commissioning Groups ((CCGs):
NHS organisations that manage patient care in GPs in defined
geographical areas): Croydon, Greenwich, Hammersmith and
Fulham, Hounslow, Lewisham, and West London. The study was
carried out in collaboration with the NHS Bowel Cancer Screening
Hub in London (hereafter referred to as ‘the hub’), who were
responsible for creating and maintaining the study database, and
iPlato (iPlato, 2013), who were responsible for randomising eligible
adults and delivering the text-message reminders. iPlato is an NHS
Information Governance approved mobile health (m-health)
organization, which provides patient care messaging services to
primary and secondary health care in England.
From age 60 and up to age 74 years, the NHS BCSP biennially
invites all men and women take part in CRC screening using the
gFOBt kit. The gFOBt pathway includes a baseline invitation to
initiate a screening episode, which is characterised as an 18-week-
long period for the adequate completion of a gFOBt kit. A week
after the initial invite, the kit is dispatched, and a reminder is sent
out on the fifth week of the initial invite if the kit had not been
returned. Unless the results are abnormal, CRC screening does not
include further investigations beyond the gFOBt pathway.
In this two-arm trial, individuals who were randomly allocated
to the control group were invited to take part in the BCSP as per
the usual care pathway, while individuals randomly allocated to the
intervention group were additionally sent a text-message reminder
if they had not returned their test kit 7 weeks into their screening
episode and had a mobile number stored on their GP’s clinical
system (see Figure 1).
Further details of the intervention design and procedures for
this RCT are available in the published protocol (Hirst et al, 2016).
GP recruitment. All GPs situated within the six CCGs were
emailed and invited to participate in this study between November
and December 2015. This invitation was followed by weekly email
reminders. Practices were eligible if they already had an existing
patient messaging service, which ensured patient consent for
text-messages. In order to facilitate automated text-messages, all
practices had to connect to the study-specific iPlato server,
irrespective of their routine m-health provider in use for text-
messages. In total, 144 out of 295 practices (48.8%) agreed to take
part and returned their consent forms. Owing to technical
difficulties, only 141 out of 144 GPs were successfully connected
to iPlato. Low response rate was considered to be an outcome of
the eligibility criteria (Hirst et al, 2016).
Trial procedures
Identification. Between January and March 2016, the hub retro-
spectively identified all men and women aged 60–74 years from all
141 practices to be included in the study based on the start date of
their gFOBt screening episode. Each week, everyone who had been
invited 7 weeks back were included, irrespective of whether or not
they had already completed and returned their faecal occult blood
test kit.
The Hub then transferred the list of the screening adults to
iPlato. The weekly file contained relevant data to the individuals’
screening statuses, including their unique identifier used within the
NHS, referred to as the ‘NHS Number’, the kit return status
(Yes/No), the date of screening invitation (Date/Month/Year) used
to calculate the date of a text-reminder, and GP code for tailored
text-messages (a unique GP identifier).
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Data processing and generation. On receipt of the data at iPlato,
individuals were randomised each week in a 1 : 1 ratio to either the
intervention or control condition. Randomisation was conducted
using Mersenne Twister: a computerised, pseudorandom number
generator (Matsumoto and Nishimura, 1998).
After randomisation, registered mobile number status (Yes/No)
was added to the weekly data file, as well as delivery status
of the text-message reminder (Yes/No) if the person was in the
intervention group and eligible to receive a text-message. The last
text-message reminder was sent on the 18 March 2016. When the
last of the individual screening episodes were closed 18 weeks after
the delivery of the baseline FOBt invitation, a complete data set was
returned via secure email transfer to the Hub.
Data merge and anonymisation. The Hub made a record of
whether or not a gFOBt had been adequately completed by the
individual within the study database and then added individual-
level data on age, gender, the name of the CCG, the screening
episode sequence number (i.e., the number of screening test kits
received by the eligible individual), and area-level of deprivation
(i.e., derived from the ‘Index of Multiple Deprivation’ (IMD) score)
to the data set. The IMD uses census-derived indicators of income,
education, employment, living environment, health and disability,
barriers to housing and services, and crime at small-area level to
generate a scale from 0 (least deprived) to 80 (most deprived). For
the purposes of our analysis, IMD scores were categorised into
quintiles of the national distribution to enable comparisons
between individuals living in the most and least deprived groups
of areas to be made. Prior to transferring to the research team for
analysis, the Hub additionally removed identifiable data (e.g., NHS
number, GP code, and postcode), which had been used to facilitate
the research.
Trial registration and ethics. The study was approved by the
East Midlands National Research Ethics Service (15/EM/0159)
and is registered with the International Standard Randomised
Controlled Trial Number (ISRCTN) registry for transparency
(ISRCTN70904476 (18/09/2015)). The study has also been
reviewed by the Confidentiality Advisory Group (CAG) and
granted full approval (15/CAG/0156), permitting iPlato to process
identifiable information for the purposes of this study to be able to
send automated text-messages from participating GPs.
Statistical analysis. The characteristics of the screening-eligible
population were demonstrated using descriptive statistics. The
primary study outcome, the proportion of invitees who returned a
test kit within 18 weeks, was assessed on an intention-to-treat
basis. A subgroup analysis using interaction terms were included to
test the intervention by invitation status (first-time invitee¼ 0;
repeat invitee¼ 1). The invitation status variable was computed by
dichotomising the screening episode sequence number. A second-
ary analysis was also performed, restricting the sample to
individuals who had not returned their kit within 8 weeks and
had a registered mobile number on their GP’s clinical system.
Analyses were conducted using multivariable logistic regression
models adjusting for sociodemographic factors (age bands, gender,
IMD quintiles, and CCG). Univariable logistic regression results
Randomised (n=8269)
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Figure 1. Study consort diagram.
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were reported (Supplementary Table S7). An exploratory analysis
was conducted to identify the predictors of having a registered
mobile number. All results are presented using odds ratios (ORs),
95% confidence intervals (CIs), and P-values. P-valueso0.05 were
considered as statistically significant.
RESULTS
Population characteristics. In total, 8269 men and women were
eligible for CRC screening and subsequently invited to the NHS
BCSP during the study identification period. Of these, 4135 were
randomised to the control group and 4134 were randomised
to the intervention group. Baseline characteristics are shown in
Table 1: Individuals invited to screening had a median age of 66
(range 65–69) years, just over half were women (52.0%), and most
had been invited to the NHS BCSP more than once (81.4%). Less
than one-tenth were from the least deprived IMD quintile (8.6%),
and about one-fifth were from the most deprived IMD quintile
(21.1%). The proportion of invitees was highest in Croydon
(21.7%), followed by Greenwich (20.7%), Hounslow (19.9%),
Lewisham (16.3%), and West London (14.5%) and lowest in
Hammersmith and Fulham (7.0%).
The impact of the intervention. Overall, 40.2% of individuals
were adequately screened; there was no significant difference
in the proportion adequately screened between the intervention
(40.5%) and control groups (39.9%; OR¼ 1.03; 95% CI: 0.94–1.12;
P¼ 0.56) (Table 2).
Factors associated with CRC screening uptake. CRC screening
uptake was lower among men than women (37.4% vs 42.8%;
OR¼ 0.80; 95% CI: 0.73–0.88; P¼ 0.001), higher among people
aged 70–74 years than those aged 60–64 years (38.2% vs 42.8%;
OR¼ 1.26; 95% CI: 1.11–1.43; Po0.001), and lower among the
most deprived IMD quintile vs least deprived quintile (34.0% vs
51.5%; OR¼ 0.53; 95% CI: 0.44–0.64; Po0.001). Uptake also
varied significantly across the six London CCGs (range from 30.5%
to 47.1%). Having a registered mobile number at the GP predicted
greater uptake than not having a registered mobile number 43.6%
vs 36.9%; OR¼ 1.31; 95% CI: 1.19–1.44 Po0.001). Limiting the
analysis to invitees with a registered mobile who did not return
their test kit by the eighth week also showed no significant
difference between the intervention (n¼ 1393, 16.6%) and the
control group (n¼ 1346; 15.9%; OR¼ 1.05; 95% CI: 0.85–1.28–
1.52 P¼ 0.67).
The impact on the intervention by invitation status. Although
there was no main intervention effect, a test of interaction showed
a significant effect of the intervention according to invitation status
(P¼ 0.02). There was a 5.6 percentage point difference between
uptake of the first-time invitees between the intervention (40.5%)
and the control groups (34.9%; OR¼ 1.29; 95% CI: 1.04–1.58;
P¼ 0.02) (Table 3). Among those who had been previously invited
to the screening programme at least once before this study, there
was no significant difference in uptake between the intervention
(41.1%) and the control group (40.5%; OR¼ 0.98; 95% CI: 0.89–
1.08, P¼ 0.66). A further exploratory analysis showed no effect of
the intervention on uptake when stratified by IMD quintiles, age
groups, CCGs, or gender (Supplementary Table S5).
Mobile phone coverage and delivery of text-messages. Mobile
phone coverage was assessed in the screening-eligible population.
Coverage varied according to age, gender, IMD score, and CCG
(Table 4). Compared with those aged 60–64 years, men and
women aged 65–69 years (OR¼ 0.85; 95% CI: 0.77–0.95;
P¼ 0.004) and 70–74 years (OR¼ 0.67; 95% CI: 0.59–0.75;
Po0.001) were less likely to have a registered mobile number.
The proportion of people with a registered mobile number
increased with area-level deprivation, with mobile registration
being 53.3% in the most deprived IMD quintile, compared with
42.7% in the least deprived IMD quintile (OR¼ 1.67; 95% CI:
1.39–2.02; Po0.001). Mobile registration at GPs also varied by
CCG. The largest proportion of individuals with registered mobile
phone numbers was observed at Croydon CCG, where coverage
was 61.9% (n¼ 1109 out of 1791). The lowest was observed in
Hammersmith and Fulham CCG, where coverage was 32.2%
(n¼ 186 out of 577; OR¼ 0.29; 95% CI: 0.24–0.36 Po0.001).
Despite differences in GP mobile phone registration, we found
no statistically significant difference in the successful delivery
of text-messages by participating CCG (P¼ 0.08), age group
(P¼ 0.09), gender (P¼ 0.45), IMD quintile (P¼ 0.41), or invitation
status (P¼ 0.07). Among 1393 people in the intervention group
with a registered mobile and no returned kit, 73.4% (n¼ 1023)
successfully received their reminders on the eighth week of their
screening episode. Further details of the delivery of text-messages
can be found in online Supplementary Materials (Supplementary
Table S6).
DISCUSSION
This trial examined the effectiveness of adding a text-message
reminder to the current NHS BCSP through the involvement of
primary care. The primary analysis showed that the intervention
was not effective at improving uptake of adequate gFOBt screening
within six CCGs in London. Likewise, the secondary analysis,
limited to individuals who had not returned their test kit within
8 weeks and had a registered mobile number at primary care,
indicated that there was no significant difference between the trial
arms. However, the subgroup analysis showed that the intervention
increased uptake of gFOBt uptake among first-time invitees from
34.9% to 40.1%.
Overall, uptake within the six CCGs (Croydon, Greenwich,
Hammersmith and Fulham, Hounslow, Lewisham, West London)
was 40.2%, which is consistent with uptake in all of London
(40.8%), reported for the first 2.6 million invitations in 2011
(von Wagner et al, 2011). The social gradient in uptake in this text-
Table 1. Sample characteristics
% (n)








Index of Multiple Deprivation
Quintile 1 (least deprived) 8.6 (705)
Quintile 2 14.1 (1157)
Quintile 3 25.0 (2044)
Quintile 4 31.1 (2544)




Hammersmith and Fulham 7.0 (577)
Hounslow 19.9 (1645)
Lewisham 16.3 (1349)
West London 14.5 (1195)
Invitation status
First-time invitees 18.6 (1542)
Repeat invitees 81.4 (6727)
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message reminder trial was consistent with the trends in first-time
and repeat CRC uptake, specifically with men consistently having
lower uptake than women, and people living in the most deprived
areas of the six CCGs having poorer uptake rates than those in
the least deprived areas (von Wagner et al, 2011; Lo et al, 2014;
Moss et al, 2016).
If CRC screening-eligible people complete their gFOBt test kit
when they are first invited, it is very likely that they will continue
to do so following subsequent invitations (Janda et al, 2010;
Lo et al, 2015b). A previous study on repeat screening participation
over two rounds of screening invitations demonstrated that
while 86% of previous responders completed their second
invitation, only 23% of the previous non-responders returned the
test kit (Lo et al, 2015a). Hence, the effect of this intervention on
the first-time invitees has important implications for the CRC
screening uptake, specifically to minimise practical barriers among
individuals who have not engaged with screening before their first
invitation.
Strengths and limitations. To our knowledge, this is the first
large-scale trial examining the effectiveness of text-message
reminders in the context of gFOBT-based CRC screening in a
nationally organised programme. The trial was purposefully
Table 2. Intention to treat and secondary analysis
Intention-to-treat (N¼8269) Secondary analysis (N¼2739)
% uptake (N) OR (95% CI) P-value % uptake (N) OR (95% CI) P-value
Study group
Control 39.9 (1648) Ref. 15.9 (214) Ref.
Intervention 40.5 (1674) 1.03 (0.94–1.12) 0.560 16.6 (231) 1.05 (0.85–1.28) 0.670
Gender
Female 42.8 (1837) Ref. 16.1 (224) Ref.
Male 37.4 (1485) 0.80 (0.73–0.88) 0.001 16.4 (221) 0.97 (0.79–1.19) 0.750
Age, years
60–64 38.2 (1407) Ref. 16.7 (233) Ref.
65–69 40.9 (1008) 1.13 (1.00–1.27) 0.050 16.9 (132) 1.14 (0.87–1.49) 0.340
70–74 42.8 (907) 1.26 (1.11–1.43) 0.000 14.2 (80) 0.97 (0.72–1.33) 0.870
Index of Multiple Deprivation
Quintile 1 (least deprived) 51.5 (363) Ref. 26.4 (178) Ref.
Quintile 2 41.9 (485) 0.79 (0.65–0.95) 0.003 23.4 (71) 0.93 (0.59–1.44) 0.740
Quintile 3 43.4 (888) 0.77 (0.64–0.95) 0.000 17.4 (113) 0.62 (0.41–0.92) 0.020
Quintile 4 38.0 (967) 0.61 (0.51–0.73) 0.000 15.0 (137) 0.52 (0.35–0.76) 0.001
Quintile 5 (most deprived) 34.0 (587) 0.53 (0.44–0.64) 0.000 11.0 (72) 0.38 (0.26–0.57) 0.000
Clinical Commissioning Groups
Croydon 47.1 (843) Ref. 18.5 (129) Ref.
Greenwich 43.3 (742) 0.89 (0.77–1.01) 0.080 17.0 (109) 0.93 (0.69–1.25) 0.640
Hammersmith and Fulham 35.9 (207) 0.68 (0.56–0.83) 0.000 14.2 (18) 0.75 (0.44–1.29) 0.290
Hounslow 40.1 (660) 0.77 (0.67–0.89) 0.000 18.6 (73) 0.95 (0.68–1.33) 0.780
Lewisham 37.5 (506) 0.73(0.63–0.85) 0.000 13.8 (77) 0.79 (0.58–1.09) 0.160
West London 30.5 (364) 0.56 (0.47–0.65) 0.000 12.0 (39) 0.65 (0.43–0.96) 0.030
Invitation status
First-time invitee 37.5 (579) Ref. 18.9 (117) Ref.
Repeat invitee 40.8 (2743) 1.01 (0.89–1.16) 0.870 15.5 (328) 0.74 (0.56–0.98) 0.040
Registered mobile number
No 36.9 (1541) Ref. NA
Yes 43.6 (1781) 1.31 (1.19–1.44) 0.000 NA
Abbreviations: CI¼ confidence interval; NA¼ not applicable; OR¼odds ratio.





% (N) % (N) OR (95% CI) P-value
Invitation status
First-time invitee 34.9 (282) 40.5 (297) 1.29 (1.04–1.58) 0.02
Repeat invitee 41.1 (1366) 40.5 (1377) 0.98 (89–1.08) 0.66
Abbreviations: CI¼ confidence interval; OR¼odds ratio.
aReference group (adjusted for age, gender, Index of Multiple Deprivation, and Clinical
Commissioning Group).
Table 4. Mobile phone coverage in London among 141
general practices
% (N) OR (95% CI) P-value
Overall 49.4 (N¼ 4089)
By gender
Female 48.4 (n¼ 2079) Ref.
Male 50.6 (n¼ 2010) 1.08 (0.99–1.18) 0.09
By age (years)
60–64 53.6 (n¼ 1972) Ref.
65–69 49.2 (n¼ 1213) 0.85 (0.77–0.95) 0.004
70–74 42.6 (n¼ 904) 0.67 (0.59–0.75) o0.001
By IMD
Quintile 1 (least deprived) 42.7 (n¼ 301) Ref.
Quintile 2 40.7 (n¼ 471) 1.24 (1.01–1.51) 0.04
Quintile 3 50.2 (n¼ 1026) 1.61 (1.34–1.93) o0.001
Quintile 4 51.7 (n¼ 1316) 1.62 (1.36–1.94) o0.001
Quintile 5 (most deprived) 53.3 (n¼ 920) 1.67 (1.39–2.02) o0.001
By CCG
Croydon 61.9 (n¼ 1109) Ref.
Greenwich 56.1 (n¼ 960) 0.79 (0.68–0.90) 0.001
Hammersmith and Fulham 32.2 (n¼ 186) 0.29 (0.24–0.36) o0.001
Hounslow 36.2 (n¼ 595) 0.35 (0.30–0.41) o0.001
Lewisham 58.1 (n¼ 784) 0.81 (0.70–0.95) 0.007
West London 38.1 (n¼ 455) 0.38 (0.32–0.44) o0.001
Abbreviations: CCG¼Clinical Commissioning Group; CI¼ confidence interval; IMD¼ Index
of Multiple Deprivation; OR¼odds ratio.
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designed to test a sustainable and a low cost (od0.05 per text)
alternative to postal reminders (second Class UK postage¼ d0.55),
with zero workload to GPs and minimal opportunity costs to the
NHS BCSP (Hirst et al, 2016). However, there may likely be a one-
off investment cost (e.g., change in IT infrastructure) to the NHS
BCSP, if text-message reminders were directly sent from the
screening programme. Unlike an appointment reminder, the text-
message reminders in CRC screening will be limited to non-
responders, if applied within NHS BCSP. Unfortunately, possible
inaccurate and out-of-date mobile numbers and low proportions of
people with registered mobile phone numbers in primary care raise
concerns that GP clinical records for mobile phone numbers may
not be up-to-date.
It is important to note a number of potential modifications,
which could improve the impact of the text-message reminder. In
this study, the reminder was sent 8 weeks after the person was
mailed their invitation. It is possible that at this point many people
would have already misplaced or thrown out their test kit. Future
research could test whether sending a text-message reminder
earlier in the episode could have more impact on uptake. Relatedly,
previous studies that have shown an effect of text-message
reminders on CRC and breast screening uptake had informed
participants at the time of initial screening invitation that they may
receive a text-message reminder (Baker et al, 2014; Kerrison et al,
2015). Sending a ‘note’ at the start of the trial may act as a ‘primer’
and enhance the impact of a text-message reminder.
CONCLUSION
GP-endorsed text-reminders at 8 weeks past the initial invitation of
CRC screening did not increase overall uptake in a socio-
economically deprived and ethnically diverse areas in London
but their positive impact on first-time invitees is promising and
could pay long-term dividends for the effectiveness of the
programme.
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